Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3045 Target Snapshot

Protein kinase C beta type · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
2,011Compounds
658Assays
4Approved Drugs
1,571.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein kinase C beta type shows late clinical disease relevance led by diabetic neuropathy. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P05771. Start with diabetic neuropathy, then reuse UniProt P05771 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with diabetic neuropathy, then reuse UniProt P05771 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
diabetic neuropathy

Protein kinase C beta type shows late clinical disease relevance led by diabetic neuropathy. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with diabetic neuropathy because it currently carries late clinical support. Linked drugs include RUBOXISTAURIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Protein kinase C beta type as ChEMBL target CHEMBL3045, mapped to UniProt P05771. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Protein kinase C beta type
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3045
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P05771
Protein kinase C beta type
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Protein kinase C beta type is the right protein anchor across sources, using UniProt P05771 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why diabetic neuropathy is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameProtein kinase C beta type
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP05771
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelProtein kinase C beta type
UniProt AccessionP05771
Component TypeProtein
Sequence Length671 aa

Protein kinase C beta type

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Protein kinase C beta type, mapped to UniProt P05771. Sequence length is 671 aa.

Mapped IDP05771
Review nameProtein kinase C beta type
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Protein kinase C beta type shows late clinical disease relevance led by diabetic neuropathy. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
diabetic neuropathy
1 linked drug · 1 direct · 1 efficacy
Linked drugRUBOXISTAURIN
Late clinical Phase III
diabetic retinopathy
1 linked drug · 1 direct · 1 efficacy
Linked drugRUBOXISTAURIN
Late clinical Phase III
Ehlers-Danlos syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugENZASTAURIN
Late clinical Phase III
glioblastoma multiforme
1 linked drug · 1 direct · 1 efficacy
Linked drugENZASTAURIN
Late clinical Phase III
non-Hodgkins lymphoma
1 linked drug · 1 direct · 1 efficacy
Linked drugENZASTAURIN
Late clinical Phase III
type 1 diabetes mellitus
1 linked drug · 1 direct · 1 efficacy
Linked drugRUBOXISTAURIN
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with diabetic neuropathy because it currently carries late clinical support. Linked drugs include RUBOXISTAURIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasediabetic neuropathy
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
6
Phase III
11
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC50878.0
KI433.0
EC505.0
KD255.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3926213 10.0 EC50 0.1 Preclinical
CHEMBL5764715 9.78 Ki 0.165 Preclinical
CHEMBL2148106 9.77 Ki 0.17 Preclinical
CHEMBL5992520 9.74 Ki 0.181 Preclinical
CHEMBL337834 9.72 Kd 0.19 Preclinical
CHEMBL4113544 9.7 EC50 0.2 Preclinical
CHEMBL2151411 9.7 IC50 0.2 Preclinical
CHEMBL6057218 9.43 Ki 0.376 Preclinical
CHEMBL285801 9.4 Ki 0.4 Preclinical
CHEMBL1256416 9.35 Ki 0.45 Preclinical
Distribution

pChEMBL Value Distribution

58
5.0
87
5.5
80
6.0
133
6.5
249
7.0
257
7.5
130
8.0
66
8.5
11
9.0
6
9.5
pChEMBL
Assay Landscape

Assay Landscape

658
Total Assays
750
Tested Compounds
3
Assay Types
Binding — 646 assays, 750 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 527 690 7.2
cell-based format 64 23 6.4
assay format 50 5 7.8
subcellular format 3 17 5.9
cell membrane format 1 4 7.4
tissue-based format 1 11 5.8
Functional — 11 assays, 15 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 7 0 —
cell-based format 4 15 7.1
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine